2021 Fiscal Year Annual Research Report
Gel vaccine designed to co-stimulate both humoral and cellular immunity ideal for elderly vaccination
| Project/Area Number |
19K10097
|
|---|
| Research Institution | Nihon University |
|---|
Principal Investigator |
Cueno Marni 日本大学, 歯学部, 専修研究員 (20569967)
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | gingival vaccine / influenza A H3N2 / influenza B/Yamagata |
|---|
| Outline of Annual Research Achievements |
We substituted the pneumolysin protein antigen with the Wuhan original SARS CoV 2 spike protein antigen since the pneumolysin protein was no longer commercially available while the original SARS CoV 2 spike protein is readily available. In this regard, we were able to successfully design molecular structures of our target antigens, namely: hemagglutinin protein of influenza A H3N2 strain, spike protein of the original SARS CoV 2, and hemagglutinin protein of influenza B/Yamagata strain. Subsequently, we were able to design and predict the ideal antigen:gel ratio (100 microgram antigen: 0.1 milligram xanthum gel) for all of our target proteins. Based on computer-based prediction, gel encapsulation of all protein antigens will make them room temperature stable. Additionally, optimization of our gingival vaccination strategy was likewise successful. Application of the antigen:gel mix along the molar teeth of the experimental rat was found to be ideal to induce an antibody response. Optimization of the standard CNS demyelination network design relative to our study is still on-going.
|
